P/E at 24.78 vs Industry's 35.77: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 24.78, considerably below the Pharmaceuticals & Biotechnology industry average of 35.77. This 30.7% discount suggests the market is pricing in either subdued growth expectations or risk factors not fully reflected in sector valuations. The sizeable gap between the stock’s P/E and the industry average invites scrutiny — Dr Reddys Laboratories Ltd’s valuation is not aligned with the broader sector’s premium, raising the question what is the current rating? The discount could reflect concerns over recent operational challenges or competitive pressures within the sector.

Performance Across Timeframes: Mixed Momentum

Examining returns over various periods reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has marginally outperformed the Sensex, with a -0.54% return compared to the benchmark’s -6.73%. However, shorter-term performance has been more volatile. The stock has declined by 8.89% over the last week, significantly underperforming the Sensex’s 1.71% loss. Similarly, the one-month return of -2.11% contrasts with the Sensex’s positive 1.88% gain. Interestingly, the three-month return of 0.96% slightly outpaces the Sensex’s 0.13%, indicating some recovery in the medium term. This divergence between short-term weakness and medium-term resilience — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — highlights the stock’s shifting momentum dynamics.

Moving Average Configuration: Bearish Technical Setup

The technical landscape for Dr Reddys Laboratories Ltd is decidedly bearish. The stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling sustained downward pressure. This configuration suggests the stock is in a prolonged downtrend, with no immediate signs of technical recovery. The six-day consecutive losing streak, resulting in a 9.71% decline, underscores the current negative momentum. The fact that the stock opened at ₹1,241.1 and has remained at this level during the trading day further reflects a lack of buying interest. Such a setup raises the question should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently. While some companies have posted gains, others have faced headwinds from regulatory challenges and pricing pressures. The sector’s average P/E of 35.77 reflects investor willingness to pay a premium for growth and innovation. Within this context, Dr Reddys Laboratories Ltd’s valuation discount stands out. The sector’s performance has been uneven, with several stocks showing positive momentum, but Dr Reddys Laboratories Ltd’s recent underperformance relative to the sector raises questions about its competitive positioning and operational outlook.

Rating Reassessment: Previously Rated Buy

On 4 May 2026, the rating for Dr Reddys Laboratories Ltd was updated from Buy to Hold by MarketsMOJO. This change reflects the evolving data landscape, including the valuation discount, recent price weakness, and technical indicators. The Mojo Score currently stands at 51.0, signalling a neutral stance. The rating reassessment invites investors to reanalyse the stock’s fundamentals and technicals — what is the current rating? The data-driven approach underscores the importance of balancing valuation appeal against momentum and sector trends.

Long-Term Performance: Outperformance Over Several Years

Despite recent volatility, Dr Reddys Laboratories Ltd has delivered solid returns over longer horizons. The three-year return of 21.19% surpasses the Sensex’s 17.37%, demonstrating resilience amid sector fluctuations. However, the five-year return of 14.72% trails the Sensex’s 45.81%, and the ten-year return of 72.82% is well below the Sensex’s 176.63%. This divergence suggests that while the stock has shown periods of strength, it has not consistently matched broader market gains over the last decade. The mixed long-term performance adds complexity to the valuation-performance tension — is this a recovery or a dead-cat bounce?

Intraday and Recent Trading Activity

On 13 July 2026, Dr Reddys Laboratories Ltd opened at ₹1,241.1 and traded inline with the sector, posting a modest gain of 0.12% for the day. This contrasts with the Sensex’s decline of 0.80%, indicating some relative strength in intraday trading. However, the stock’s six-day losing streak and cumulative 9.71% decline over that period highlight persistent selling pressure. The inability to break above key moving averages suggests that short-term rallies may face resistance, reinforcing the cautious technical outlook.

Summary: What the Data Collectively Shows

The data for Dr Reddys Laboratories Ltd paints a picture of valuation discount amid sector premiums, mixed short- and medium-term performance, and a bearish technical setup. The stock’s P/E ratio of 24.78 versus the industry’s 35.77 indicates a significant market discount, possibly reflecting concerns over recent momentum and competitive pressures. While the one-year return slightly outperforms the Sensex, recent weeks have seen sharp declines and a technical downtrend below all major moving averages. The rating reassessment from Buy to Hold on 4 May 2026 aligns with this data-driven narrative, signalling a more cautious stance. Investors may find value in analysing the balance between valuation appeal and momentum risks — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →